Combination ATR and PARP Inhibitor (CAPRI) Trial With AZD6738 and Olaparib in Recurrent Ovarian Cancer

NCT03462342 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

123

Enrollment

OTHER

Sponsor class

Conditions

High Grade Serous Carcinoma

Interventions

DRUG: Olaparib Pill
DRUG: AZD6738

Sponsor

University of Pennsylvania

Collaborators

AstraZeneca